• PAO1- COST-EFFECTIVENESS ANALYSIS OF NSAIDS VS COX-2 SPECIFIC INHIBITORS AND NSAIDS WITH CO-TREATMENTS TO PREVENT Gl TOXICITY IN THE TREATMENT OF RA

    Sep 1, 2000, 00:00

  • PMDP3- THE FRENCH HEALTH UTILITIES INDEX MARK 3

    Sep 1, 2000, 00:00

  • PCV22- COST-EFFECTIVENESS OF HMG-CoA REDUCTASE INHIBITORS AND FIBRATES THERAPY IN ELDERLY WOMEN WITH CORONARY ARTERY DISEASE

    Sep 1, 2000, 00:00

  • RS2- SYMPTOM-BASED OUTCOME MEASURES FOR ASTHMA

    Sep 1, 2000, 00:00

  • PCV29- SUPPORTING IMPLEMENTATION OF PRESCRIPTION GUIDELINES IN MEDICAL WARDS- A RANDOMIZED TRIAL

    Sep 1, 2000, 00:00

  • PMDM2- GUIDING PRINCIPLES TO COMPARE THE EFFICACY OF NOVEL DRUGS USING RCT MATCHED ARM COMPARISONS

    Sep 1, 2000, 00:00

  • PMH11- DEINSTITUTIONALIZATION MODEL IN SCHIZOPHRENIA- COST-CONSEQUENCES OF INTENSIVE CASE MANAGEMENT VERSUS STANDARD CASE MANAGEMENT

    Sep 1, 2000, 00:00

  • PID6- CANADIAN COST-EFFECTIVENESS OF COMBINATION RIBAVIRIN/INTERFERON ALPHA-2B THERAPY FOR TREATMENT-NAIVE VIRAL HEPATITIS C

    Sep 1, 2000, 00:00

  • PNR7- COST-EFFECTIVENESS ANALYSIS OF ENTACAPONE IN ADVANCED PARKINSONS DISEASE A MARKOV PROCESS ANALYSIS

    Sep 1, 2000, 00:00

  • PGS5- APPRAISAL OF ERECTILE DYSFUNCTION- WHOSE VALUES SHOULD BE USED?

    Sep 1, 2000, 00:00

  • PCH11- PAYER COSTS OF PANCREATIC CANCER IN A NONELDERLY MEDICAID POPULATION

    Sep 1, 2000, 00:00

  • PCV5- ECONOMIC EVALUATION OF RAMIPRIL IN THE TREATMENT OF PATIENTS AT HIGH RISK OF CARDIOVASCULAR EVENTS

    Sep 1, 2000, 00:00

  • PNR5- THE LONG-TERM ECONOMIC IMPACT OF TREATING ALZHEIMERS PATIENTS IN SWEDEN WITH GALANTAMINE

    Sep 1, 2000, 00:00

  • PMDP1- WILLINGNESS TO PAY FOR AVOIDING ADVERSE EFFECTS OF DRUGS

    Sep 1, 2000, 00:00

  • PID10- COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTIC PROPHYLAXIS IN INTRA-ABDOMINAL SURGERY

    Sep 1, 2000, 00:00

  • PRS7- AN ECONOMIC IMPACT OF A DUR INTERVENTION ON THE PHARMACOLOGICAL MANAGEMENT OF ASTHMA IN CHILDREN

    Sep 1, 2000, 00:00

  • CN3- COST-SAVINGS FOR CAPECITABINE DUE TO ORAL ADMINISTRATION IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER

    Sep 1, 2000, 00:00

  • PCN12- CHANGES IN OUTPATIENT DRUG COSTS FOR CANCER PATIENTS, 1995 vs 1998

    Sep 1, 2000, 00:00

  • PCV24- THE COST OF REACHING LDL-C TARGETS IN SPAIN- A COMPARISON AMONG STATINS

    Sep 1, 2000, 00:00

  • PMDQ3- HEALTH-RELATED QUALITY OF LIFE AMONG FRENCH PATIENTS HOSPITALIZED IN INTERNAL MEDICINE

    Sep 1, 2000, 00:00

  • PNH6- ANTIPSYCHOTIC TREATMENT, ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PNR6- SUBJECTIVE AND OBJECTIVE QUALITY OF LIFE CHANGE SCORES IN A SHORT-TERM EPILEPSY STUDY

    Sep 1, 2000, 00:00

  • PRS4- A HEALTH ECONOMIC MODEL TO DESCRIBE THE CURRENT AND EXPECTED BURDEN OF COPD

    Sep 1, 2000, 00:00

  • PMH5- IMPACT OF AMISULPRIDE ON HEALTH CARE RESOURCES IN SCHIZOPHRENIA- PRELIMINARY RESULTS OF A FRENCH STUDY

    Sep 1, 2000, 00:00

  • CV6- A MULTICENTER STUDY OF PHARMACIST DIRECTED INTERVENTIONS IN DYSLIPIDEMIA THERAPY

    Sep 1, 2000, 00:00

  • PRS9- PROBLEMATIC ISSUES OF THE QUALITY OF ASTHMA MANAGEMENT IN RURAL AREAS IN GREECE

    Sep 1, 2000, 00:00

  • PMH13- THE MEDICAL COSTS OF DEMENTIA IN BELGIUM- RESULTS OF THE NADES STUDY

    Sep 1, 2000, 00:00

  • PCV15- ANTI-HYPERTENSIVE AGENTS AND THE RISK OF HIP OR WRIST FRACTURES IN AN OTHERWISE HEALTHY COMMUNITY POPULATION

    Sep 1, 2000, 00:00

  • PMDP2- CONSUMER USE OF THE INTERNET FOR HEALTHCARE INFORMATION

    Sep 1, 2000, 00:00

  • PMH15- ECONOMIC EVALUATION OF REBOXETINE FOR TREATING MAJOR DEPRESSION

    Sep 1, 2000, 00:00

  • PAO10- ANNUAL COST OF TREATING CARPAL TUNNEL SYNDROME IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • CV4- THE INFLUENCE OF NON-CARDIAC VASCULAR DISEASE ON THE COST-EFFECTIVENESS OF SCREENING FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

    Sep 1, 2000, 00:00

  • PID2- PHARMACOECONOMIC EVALUATION OF IMMUNOPROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK INFANTS

    Sep 1, 2000, 00:00

  • PCV8- HOSPITALIZATION COSTS AFTER FIRST ACUTE CORONARY SYNDROME- A COMBINED MODEL APPROACH

    Sep 1, 2000, 00:00

  • PGU6- DEVELOPMENT AND INITIAL PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-QUALITY OF LIFE INSTRUMENT (PAGI-QOL) IN Gl PATIENTS

    Sep 1, 2000, 00:00

  • PGU1- IS HEALTH-RELATED QUALITY OF LIFE (HRQL) IMPROVED BY GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) DRUGS?

    Sep 1, 2000, 00:00

  • PCV1- THE ATRIAL FIBRILLATION ANTITHROMBOSIS MODEL (AFAM)- A GENERAL-PURPOSE TOOL FOR ANALYSIS, POLICY-MAKING, AND EDUCATION

    Sep 1, 2000, 00:00

  • RS1- COMPARISON OF IMPUTATION METHODS FOR MISSING ASTHMA QUALITY OF LIFE DATA

    Sep 1, 2000, 00:00

  • PCV7- INCREMENTAL COST-EFFECTIVENESS RATIO IN ESTIMATION SOME HYPOTENSIVE DRUGS

    Sep 1, 2000, 00:00

  • PCN14- THE USE OF TRANSDERMAL FENTANYL (FEN) VERSUS MORPHINE (MOR) IN CANCER PAIN PATIENTS IN ISRAEL

    Sep 1, 2000, 00:00

  • PCV6- GENDER DIFFERENCES IN THE QUALITY OF LIFE AND COMPLIANCE WITH ROUTINE TREATMENT OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY

    Sep 1, 2000, 00:00

  • PMH10- SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC TREATMENT AND COMPLIANCE IN SCHIZOPHRENIA

    Sep 1, 2000, 00:00

  • PAO3- DIRECT MEDICAL COST OF CHRONIC POLYARTHRITIS IN GERMANY

    Sep 1, 2000, 00:00

  • PCV11- DETERMINANTS OF COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH OPEN HEART SURGERY

    Sep 1, 2000, 00:00

  • DB2- AGGREGATION OF WILLINGNESS-TO-PAY MEASURED IN DECOMPOSED SCENARIOS

    Sep 1, 2000, 00:00

  • PMH4- CLINICAL, HUMANISTIC, AND ECONOMIC OUTCOMES ASSOCIATED WITH LONG-TERM TREATMENT OF MANIA WITH OLANZAPINE

    Sep 1, 2000, 00:00

  • PMDQ1- GENERAL POPULATION-BASED QUALITY OF LIFE MEASUREMENTS USING THE EQ-5D QUESTIONNAIRE

    Sep 1, 2000, 00:00

  • PGU17- FACTORS ASSOCIATED WITH SELECTING MEDICATION TO TREAT PATIENTS NEWLY DIAGNOSED WITH OVERACTIVE BLADDER

    Sep 1, 2000, 00:00

  • PDB5- THE ECONOMIC BURDEN OF TYPE 2 DIABETES ON THE INDIVIDUAL

    Sep 1, 2000, 00:00

  • PMDQ2- CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98- BY DECLARED REGULARITY OF PHARMACEUTICAL DRUG INTAKE

    Sep 1, 2000, 00:00

  • AO2- GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE MEASUREMENTS IN 127 RHEUMATOID ARTHRITIS AND 167 OSTEOARTHRITIS PATIENTS IN HUNGARY

    Sep 1, 2000, 00:00

  • CH2- RELATING QUALITY ADJUSTED LIFE YEARS TO CONTINGENT VALUATION- ACUTE VERSUS CHRONIC ILLNESSES

    Sep 1, 2000, 00:00

  • PMDE2- THE COST OF GLAUCOMA TREATMENT IN POLAND-RESULTS FROM OBSERVATIONAL STUDY

    Sep 1, 2000, 00:00

  • PMDH3- THE USE OF SURROGATE ENDPOINT DATA IN EVALUATING TREATMENT EFFICACY- IMPACT ON DECISION-MAKING AND EXPENDITURE WITHIN THE AUSTRALIAN PHARMACEUTICAL BENEFITS SCHEME

    Sep 1, 2000, 00:00

  • PRS3- EUROQOL EQ-5D- DISCRIMINANT VALIDITY IN RESPIRATORY DISEASE

    Sep 1, 2000, 00:00

  • PNR8- A CANADIAN ADAPTATION OF A DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOIDS FOR CHRONIC PAIN

    Sep 1, 2000, 00:00

  • PRS12- COST OF ILLNESS ON PATIENTS IN A PUBLIC HOSPITAL WITH SEVERE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAY DISEASE

    Sep 1, 2000, 00:00

  • ID3- PRELIMINARY EVALUATION OF THE CLINICAL AND ECONOMIC BENEFITS OF UNIVERSAL VARICELLA VACCINATION OF CHILDREN IN GERMANY

    Sep 1, 2000, 00:00

  • PCV23- VARIATION IN COSTS OF TREATING HYPERCHOLESTEROLEMIC PATIENTS IN FRANCE

    Sep 1, 2000, 00:00

  • PGS1- ALOPECIA, PSYCHOLOGICAL DISTRESS AND QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PCV27- TREATMENT OF CHRONIC HEART FAILURE (CHF)- IMPROVING SURVIVAL BUT NOT HEALTH-RELATED QUALITY OF LIFE (HRQL)

    Sep 1, 2000, 00:00

  • PDB7- HEALTH RELATED QUALITY OF LIFE IN TYPE 2 DIABETES

    Sep 1, 2000, 00:00

  • PMDP4- THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES

    Sep 1, 2000, 00:00

  • PGU18- PREVALENCE OF BLADDER CONTROL PROBLEMS IN A LARGE GERMAN POPULATION SAMPLE

    Sep 1, 2000, 00:00

  • DBS- A FIVE YEAR LONGITUDINAL ANALYSIS OF THE HEALTH BENEFITS OF TRANSITIONING TO INSULIN THERAPY SOONER IN THE MANAGEMENT OF NEWLY DIAGNOSED TYPE II DIABETICS

    Sep 1, 2000, 00:00

  • PID11- THE PEACE PROJECT (PRESCRIPTION AND EFFECTIVENESS OF ANTIBIOTIC IN CLINICAL EXPERIENCE)- RESULTS OF THE FEASIBILITY STUDY

    Sep 1, 2000, 00:00

  • PCV9- PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AND FATAL PULMONARY EMBOLISM IN KNEE ARTHROPLASTIES- A COST-EFFECTIVENESS STUDY

    Sep 1, 2000, 00:00

  • PNR1- COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

    Sep 1, 2000, 00:00

  • PMDM1- POWER AND SAMPLE SIZE CALCULATIONS FOR A CLINICAL TRIAL CONSIDERING COST-EFFECTIVENESS AND STATISTICAL ERRORS

    Sep 1, 2000, 00:00

  • PAO2- A COST-COST STUDY COMPARING ETANERCEPT WITH INFLIXIMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2000, 00:00

  • PID7- MULTITHERAPIES- TOWARDS COST-SAVING STRATEGIES IN REAL LIFE?

    Sep 1, 2000, 00:00

  • PMDH1O- REIMBURSED DRUG REGULATION- COMPARING TWO MODELS FOR CONTROL DRUGS CONSUMPTION IN ISRAEL USING PERMEATION COEFFICIENT PARAMETER.

    Sep 1, 2000, 00:00

  • PGU7- IN FINLAND, SWEDEN AND THE UK, ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS

    Sep 1, 2000, 00:00

  • PDB1- VARIATIONS IN MEDICATION UTILIZATION IN AN OLDER DIABETIC POPULATION

    Sep 1, 2000, 00:00

  • CH1- COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER

    Sep 1, 2000, 00:00

  • PGU2- DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN Gl PATIENTS

    Sep 1, 2000, 00:00

  • PMDE6- EVALUATION OF THE VALIDITY OF RETROSPECTIVE QOL OUTCOMES

    Sep 1, 2000, 00:00

  • PCN5- EVALUATION OF THREE DIFFERENT METHODS OF ASSESSING WILLINGNESS TO PAY FOR A NEW DRUG IN THE GENERAL POPULATION

    Sep 1, 2000, 00:00

  • PGU3- DECISION ANALYSIS OF OMEPRAZOLE VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION FOR TREATING PATIENTS WITH SEVERE GASTROESOPHAGEAL REFLUX DISEASE

    Sep 1, 2000, 00:00

  • PID3- COST-EFFECTIVENESS OF HEPATITIS B VACCINATION IN THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PMDH6- AN ECONOMIC EVALUATION OF PHARMACEUTICAL COST CONTAINMENT POLICIES IN ALBERTA, CANADA

    Sep 1, 2000, 00:00

  • PMDH9- ATLAS OF AVOIDABLE DEATHS IN ITALY

    Sep 1, 2000, 00:00

  • CV1- IS QUALITY OF LIFE A VALID OUTCOME FOR VARICOSE VEINS SURGERY? RESULTS OF AN INTERNATIONAL EPIDEMIOLOGICAL STUDY

    Sep 1, 2000, 00:00

  • PDB4- EFFECT OF A POLICY CHANGE ON USE OF BLOOD GLUCOSE MONITORS BY DIABETICS WITH MEDICARE COVERAGE

    Sep 1, 2000, 00:00

  • PCV12- A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL IN THE TREATMENT OF HYPERTENSION IN EUROPE

    Sep 1, 2000, 00:00

  • PCU16- ADAPTING A US COST-OFFSET ECONOMIC MODEL FOR OVERACTIVE BLADDER FOR THE EUROPEAN MARKETPLACE

    Sep 1, 2000, 00:00

  • PGU1O- IRRITABLE BOWEL SYNDROME (IBS) IN GERMANY- A COST OF ILLNESS STUDY

    Sep 1, 2000, 00:00

  • PMDH1- NICE REQUIREMENTS FOR COST-EFFECTIVENESS EVIDENCE- POTENTIAL SAMPLE SIZE IMPLICATIONS OF GENERATING TRIAL-BASED EVIDENCE

    Sep 1, 2000, 00:00

  • GU3- ERADICATION OF HELICOBACTER PYLORI TO PREVENT PEPTIC ULCERS PRIOR TO NSAID THERAPY-A COST-EFFECTIVENESS ANALYSIS

    Sep 1, 2000, 00:00

  • PGU15- COSTS AND RESOURCES ASSOCIATED WITH THE TREATMENT OF OVERACTIVE BLADDER USING RETROSPECTIVE MEDICAL CARE CLAIMS DATA

    Sep 1, 2000, 00:00

  • PNR2- THE ROLE OF COGNITIVE METHODS IN THE DESIGN OF CONJOINT ANALYSIS TO EVALUATE EPILEPSY TREATMENTS

    Sep 1, 2000, 00:00

  • PRS6- QUALITY OF LIFE AND TREATMENT SATISFACTION MEASUREMENT WITH ASTHMA PATIENTS- RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW

    Sep 1, 2000, 00:00

  • PGU5- THE BURDEN OF ILLNESS OF IRRITABLE BOWEL SYNDROME (IBS) USING THE ROME II CRITERIA

    Sep 1, 2000, 00:00

  • PRS1- TO COMPARE AND CONTRAST THE QUALITY OF LIFE (QOL) OF INDIVIDUALS WITH CHRONIC BRONCHITIS, DURING THE STABLE PHASE AND ACUTE EXACERBATIONS

    Sep 1, 2000, 00:00

  • PID1- ASSOCIATED OUTCOMES OF INFLUENZA-LIKE-ILLNESS AND CLINICAL INFLUENZA IN ITALY

    Sep 1, 2000, 00:00

  • PCN6- QUALITY OF LIFE ASSESSMENT OF DOCETAXEL TREATED PATIENTS IN ADVANCED BREAST CANCER

    Sep 1, 2000, 00:00

  • PNR3- A COST MINIMIZATION MODEL FOR 2-1 THERAPEUTIC INTERCHANGE PROTOCOLS OF MEDICATIONS WITH HIGHLY VARIABLE DOSING REGIMENS

    Sep 1, 2000, 00:00

  • PAO7- COST-OF-ILLNESS STUDIES IN GERMANY WITH OSTEOPOROSIS AS EXAMPLE

    Sep 1, 2000, 00:00

  • PRS18- USE OF PHARMACOTHERAPY AS AN ASTHMA SEVERITY MEASURE IN A RETROSPECTIVE ANALYSIS

    Sep 1, 2000, 00:00

  • MD2- MEASURING REDUCED PRODUCTIVITY DURING PAID LABOR

    Sep 1, 2000, 00:00

  • PAO9- IS RESIDRONATE MORE COST-EFFECTIVE THAN ETIDRONATE FOR FRACTURE PREVENTION? A COST-UTILITY ANALYSIS

    Sep 1, 2000, 00:00

  • NR1- PATIENTS REPORTED HEALTH STATUS AND UTILITIES FOR AMYOTROPHIC LATERAL SCLEROSIS

    Sep 1, 2000, 00:00

  • PCV3- THE COST-EFFECTIVENESS OF TREATING CHLAMYDIA PNEUMONIAE INFECTION FOR THE PREVENTION OF CORONARY HEART DISEASE

    Sep 1, 2000, 00:00

  • PDB6- THE FINANCIAL EFFECTS OF INTERFACE AGREEMENTS FOR DIABETES MELLITUS- SOCIOECONOMIC RELEVANCE OF INTENSIVE CONTROLLED INSULIN THERAPY WITH INSULIN LISPRO COMPARED TO REGULAR HUMAN INSULIN

    Sep 1, 2000, 00:00

  • PMDH8- DO DECISION-MAKERS FIND ECONOMIC EVALUATIONS USEFUL? RESULTS OF FOCUS GROUP RESEARCH IN THE UK

    Sep 1, 2000, 00:00

  • ID1- MODELLING THE COSTS AND EFFECTS OF CMV MANAGEMENT STRATEGIES IN TRANSPLANT RECIPIENTS AS A SUPPORT FOR CURRENT AND FUTURE DECISION-MAKING

    Sep 1, 2000, 00:00

  • PGU14- MODELLING OF AN ANTIOBESITY TREATMENT- COST-EFFECTIVENESS MODEL IN THE UK

    Sep 1, 2000, 00:00

  • CV3- IMPACT OF CARVEDILOL ON INPATIENT RESOURCE USE AND COSTS IN HEART FAILURE

    Sep 1, 2000, 00:00

  • MH3- VALIDATION OF A METHODOLOGY FOR ESTIMATING PRODUCTIVITY GAINS FROM IMPROVEMENTS IN HAM-D SCORES

    Sep 1, 2000, 00:00

  • DB1- TWO-PART MODELS FOR DEMAND OF HOSPITAL TREATMENT IN TYPE II DIABETIC PATIENTS

    Sep 1, 2000, 00:00

  • PRS16- ECONOMIC IMPACT OF THE RESPIRATORY SYNCYTIAL VIRUS DISEASE, FRENCH SOCIETAL PERSPECTIVE

    Sep 1, 2000, 00:00

  • PID8- COST-EFFECTIVENESS OF CIPROFLOXACIN HYDROCORTISON IN THE TREATMENT OF ACUTE OTITIS EXTERNA

    Sep 1, 2000, 00:00

  • GS1- AN INVESTIGATION OF FACTORS USED BY PATIENTS FOR DRUG TREATMENT DECISION-MAKING- AN EXAMINATION OF THERAPY OPTIONS FOR ERECTILE DYSFUNCTION

    Sep 1, 2000, 00:00

  • PRS11- IMPACT OF BRONCHIAL ASTHMA ON CHILDS QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PCV4- COST-EFFECTIVENESS OF DOXAZOSIN IN COMBINATION THERAPY FOR HYPERTENSION TREATMENT IN DIABETIC PATIENTS IN THE UK

    Sep 1, 2000, 00:00

  • PMH17- COST OF TREATING SIDE EFFECTS OF SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs) IN A HEALTH MAINTENANCE ORGANIZATION (HMO)

    Sep 1, 2000, 00:00

  • PMDM3- PROJECTING ECONOMIC RESULTS OF A EUROPEAN TRIAL TO THE UNITED STATES- ISSUES AND METHODS

    Sep 1, 2000, 00:00

  • AO1- IMPACT OF POST-FRACTURE TREATMENT COSTS AND MODEL TIME HORIZON ON COST-EFFECTIVENESS OF OSTEOPOROSIS THERAPIES

    Sep 1, 2000, 00:00

  • PHDH7- INTERNATIONAL COMPARISON OF PHARMACOECONOMIC GUIDELINES- CONSENSUS, DIVERGENCE AND PRACTICAL IMPLICATIONS

    Sep 1, 2000, 00:00

  • PID12- THE IMPACT OF PRICE ELASTICITY OF DEMAND ON CONSUMPTION-AMPICILLIN/ AMOXICILLIN MARKET SURVEY IN BULGARIA, 1995 AND 1999

    Sep 1, 2000, 00:00

  • PCN4- ECONOMIC CONSEQUENCES OF DIFFERENCES IN THE ADVERSE-EVENTS (AE) PROFILE OF CAPECITABINE vs. MAYO CLINIC (M) -REGIMEN IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER.

    Sep 1, 2000, 00:00

  • PID9- PATIENTS COMPLIANCE AND COST-EFFECTIVENESS OF SELECTED ORAL ANTIBACTERIALS IN INPATIENT TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS

    Sep 1, 2000, 00:00

  • PCN1O- COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC CLODRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND

    Sep 1, 2000, 00:00

  • PCV28- SAVINGS ACHIEVED IN AN HMO SPONSORED PRIMARY CARE BASED DISEASE MANAGEMENT AND CASE MANAGEMENT INITIATIVE

    Sep 1, 2000, 00:00

  • ID2- COST-EFFECTIVENESS ANALYSIS OF HEXAVALENT MENINGOCOCCAL B OUTER-MEMBRANE-VESICLE VACCINE

    Sep 1, 2000, 00:00

  • PID14- MODELING PHYSICIAN PREFERENCES IN ANTIBIOTIC CHOICE

    Sep 1, 2000, 00:00

  • PMDQ4- CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98- PSYCHOMETRICS OF THE MINI QLCS ASSESSMENT BATTERY APPLIED

    Sep 1, 2000, 00:00

  • PGS7- ISSUES IN USING CONJOINT ANALYSIS TO VALUE HEALTH CARE WITHIN CLINICAL STUDIES

    Sep 1, 2000, 00:00

  • PGS2- PHARMACOECONOMIC MODELING IN ASSISTED REPRODUCTION TECHNOLOGIES- RECOMBINANT FSH VERSUS URINARY FSH

    Sep 1, 2000, 00:00

  • PCV26- COST OF CARE AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS IN EMILIA ROMAGNA REGION (ITALY)- RESULTS FROM THE GREAT STUDY

    Sep 1, 2000, 00:00

  • PCV18- COST-EFFECTIVENESS OF PREVENTION OF ATHEROTHROMBOTIC DISEASE WITH ASPIRIN VERSUS CLOPIDOGREL IN GREECE

    Sep 1, 2000, 00:00

  • PMH14- COST OF CARE IN SCHIZOPHRENIA PATIENTS-RESULTS FROM THE NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

    Sep 1, 2000, 00:00

  • NH2- ATYPICAL ANTIPSYCHOTICS AND THE RISK OF DEVELOPING DIABETES

    Sep 1, 2000, 00:00

  • PCV14- USING THE GENERAL PRACTICE RESEARCH DATABASE TO GENERATE AN 'AT RISK REGISTER' FOR A PRIMARY CARE STROKE PREVENTION PROGRAM

    Sep 1, 2000, 00:00

  • PMDE3- COST-EFFECTIVENESS ANALYSIS OF CONTINOUS TERBINAFINE VS INTERMITTENT ITRACONAZOLE IN THE TREATMENT OF TOENAIL ONYCHOMYCOSIS IN POLAND

    Sep 1, 2000, 00:00

  • MH1- PATTERNS OF USE OF ANTIDEPRESSANT AND CONCOMITANT PSYCHOTROPICS

    Sep 1, 2000, 00:00

  • NR3- ECONOMIC EVALUATION OF TRANSDERMAL FENTANYL IN THE TREATMENT OF CHRONIC NON-CANCER PAIN IN DENMARK

    Sep 1, 2000, 00:00

  • PNH2- EVALUATION OF THE CES-D IN SIX COUNTRIES USING RASCH ITEM RESPONSE THEORY (IRT) ANALYSIS

    Sep 1, 2000, 00:00

  • PRS5- COST-EFFECTIVENESS OF EMEDASTINE VERSUS LEVOCABASTINE IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS

    Sep 1, 2000, 00:00

  • PCV2O- ANNUAL COST OF TREATING HYPERLIPIDEMIA IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • PCN7- FAMILY CAREGIVING COSTS FOR THE ELDERLY WITH CANCER- ESTIMATES FROM A REPRESENTATIVE SAMPLE OF THE UNITED STATES

    Sep 1, 2000, 00:00

  • PGU9- EVALUATION OF THE DIRECT COST OF CARE FOR PATIENTS SUFFERING FROM HEMORRHOIDS

    Sep 1, 2000, 00:00

  • PCV13- COSTS ASSOCIATED WITH HEALTH SERVICES UTILIZATION IN PATIENTS WITH VARICOSE VEINS

    Sep 1, 2000, 00:00

  • PCH2- THE LEVEL OF HAEMOGLOBIN (Hb) IN U.K. CANCER PATIENTS CORRELATES POSITIVELY WITH QUALITY OF LIFE (QoL)

    Sep 1, 2000, 00:00

  • PMH16- RELAPSE IN SCHIZOPHRENIA- COSTS AND QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PRS15- OUTCOMES RESEARCH STUDY ASSESSING RESOURCE UTILIZATION FOR THE TREATMENT OF ASTHMA EXACERBATION IN PRIMARY CARE IN SPAIN

    Sep 1, 2000, 00:00

  • PMH8- PHARMACOECONOMIC MODELLING IN DEPRESSION- AID OR TRAP

    Sep 1, 2000, 00:00

  • MD1- AVOIDABLE HOSPITALIZATION- TRENDS AND ETHNIC VARIATIONS IN SINGAPORE, 1991-1998

    Sep 1, 2000, 00:00

  • PAO6- BUDGETARY IMPACT ANALYSIS FOR USE IN REIMBURSEMENT PROCESS OF ETANERCEPT IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2000, 00:00

  • PMDH4- DIFFERING LEVELS OF PATIENT SATISFACTION WITH PHARMACY SERVICES IN A MANAGED CARE ORGANIZATION

    Sep 1, 2000, 00:00

  • PCN15- A METHODOLOGY FOR IMPLEMENTING QUALITY-ADJUSTED DISEASE FREE SURVIVAL (QADFS) WITH MULTIDIMENSIONAL QUALITY OF LIFE (QoL) INSTRUMENTS IN CANCER TRIALS

    Sep 1, 2000, 00:00

  • PCN8- COST-UTILITY ANALYSIS OF SEVERAL SECOND-LINE CHEMOTHERAPY SCHEMES FOR PATIENTS WITH METASTATIC BREAST CANCER

    Sep 1, 2000, 00:00

  • GU1- THE WILLINGNESS TO PAY FOR REDUCED URGE INCONTINENCE

    Sep 1, 2000, 00:00

  • PGS8- ECONOMIC ASSESSMENT OF THE DIRECT SPECIFIC COST OF BENIGN PROSTATIC HYPERPLASIA IN FRANCE, HEALTH INSURANCE PERSPECTIVE

    Sep 1, 2000, 00:00

  • PMDM4- MEASUREMENTS OF HEALTH STATUS IN DENMARK

    Sep 1, 2000, 00:00

  • PDB2- COST-EFFECTIVENESS OF A NEW HUMAN DERMAL REPLACEMENT FOR THE TREATMENT OF DIABETIC FOOT ULCERS- THE CASE OF FRANCE

    Sep 1, 2000, 00:00

  • PGU12- IN FINLAND, SWEDEN AND THE UK, ON DEMAND TREATMENT WITH ESOMEPRAZOLE IS COST-EFFECTIVE IN PATIENTS WITH GORD WITHOUT OESOPHAGITIS

    Sep 1, 2000, 00:00

  • PHDE4- PHARMACOECONOMIC EVALUATION OF CALCIPOTRIOL AND UVB IN THE TREATMENT OF PSORIASIS IN THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PRS14- ASTHMA AND ANTI-ASTHMA DRUG USE IN HUNGARY

    Sep 1, 2000, 00:00

  • GS2- DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION MODULE FOR USE WITH MENOPAUSAL WOMEN

    Sep 1, 2000, 00:00

  • PCV25- THE COST OF STROKE IN GREECE IN 1998

    Sep 1, 2000, 00:00

  • AO3- QUALITY OF LIFE AFTER OSTEOPOROTIC FRACTURES IN DUTCH MEN AND WOMEN

    Sep 1, 2000, 00:00

  • PGS3- AN ASSESSMENT OF THE RELATION BETWEEN SILDENAFIL USE AND QUALITY OF LIFE DIMENSIONS

    Sep 1, 2000, 00:00

  • PRS17- EPIDEMIOLOGY AND COSTS OF BRONCHIAL ASTHMA AND CHRONIC BRONCHITIS IN GERMANY

    Sep 1, 2000, 00:00

  • PCV1O- RETROSPECTIVE MEDICAL RECORD REVIEW TO DETERMINE THE 'AT GOAL' PATIENTS WITH HYPERTENSION AND/OR DYSLIPIDEMIA

    Sep 1, 2000, 00:00

  • PHH7- TREATMENT PATTERNS OF PATIENTS WITH SCHIZOPHRENIA AND SCHIZO-AFFECTIVE DISORDER ACROSS 15 COUNTRIES

    Sep 1, 2000, 00:00

  • PCN3- COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC PAMIDRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND (COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS)

    Sep 1, 2000, 00:00

  • CV5- AN ECONOMIC EVALUATION OF TINZAPARIN COMPARED TO STANDARD HEPARIN IN TREATING PULMONARY EMBOLISM

    Sep 1, 2000, 00:00

  • PCV17- VARIABILITY IN ABCIXIMAB (REOPRO) USAGE- EVIDENCE-BASED OR BUDGET-DRIVEN?

    Sep 1, 2000, 00:00

  • PRS13- ANNUAL COST OF TREATING RHINITIS IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • PGU11- DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN GASTROPARESIS

    Sep 1, 2000, 00:00

  • PCN13- MANAGEMENT OF LUNG CANCER IN FRANCE

    Sep 1, 2000, 00:00

  • GS3- THE VALUATION OF DISEASE-SPECIFIC HEALTH STATES TO FACILITATE ECONOMIC EVALUATION OF PHARMACEUTICALS

    Sep 1, 2000, 00:00

  • PRS8- TREATMENT AND ASSOCIATED COSTS OF NEWLY DIAGNOSED COPD PATIENTS IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • PCV16- COST-EFFECTIVENESS OF LOW-MOLECULAR WEIGHT HEPARIN VERSUS ORAL ANTICOAGULANTS FOR SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM

    Sep 1, 2000, 00:00

  • PAO5- THE COSTS OF RHEUMATOID ARTHRITIS- IS THERE A NEED FOR STANDARDIZATION OF METHODS?

    Sep 1, 2000, 00:00

  • PDB3- USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES

    Sep 1, 2000, 00:00

  • PMH3- GLOBAL INDEX OF SAFETY (GIS)- A NEW INSTRUMENT TO ASSESS DRUG SAFETY- APPLICATION TO A PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY (EFESO)

    Sep 1, 2000, 00:00

  • MD3- A NEW INDEX APPROACH TO MEASURE THE BENEFITS OF DELAYING THE PROGRESSION TO BLINDNESS

    Sep 1, 2000, 00:00

  • PCV19- TURKISH PHYSICIAN PRESCRIPTION PATTERNS FOR HYPERTENSION MANAGEMENT

    Sep 1, 2000, 00:00

  • PID13- COST-EFFECTIVENESS OF GANCICLOVIR IN PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER LIVER TRANSPLANTATION- A BAYESIAN APPROACH

    Sep 1, 2000, 00:00

  • PGS6- METHODOLOGICAL ISSUES IN EVALUATING CONCEPTUAL EQUIVALENCE- APPLICATION TO THE WOMENS HEALTH QUESTIONNAIRE (WHQ)

    Sep 1, 2000, 00:00

  • PCV2- POPULATION PROJECTIONS OF CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY ASSOCIATED WITH ROFECOXIBS EFFECT ON SYSTOLIC BLOOD PRESSURE

    Sep 1, 2000, 00:00

  • PAO4- COX-II INHIBITORS AND NSAIDS- FINDINGS OF A NICE SUBMISSION

    Sep 1, 2000, 00:00

  • PGU13- ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH NON-ENDOSCOPED GORD IN THE UK

    Sep 1, 2000, 00:00

  • PCH1- PAMIDRONATE FOR BREAST CANCER PATIENTS WITH SKELETAL METASTASES- A MARKOV TREE-BASED COST-UTILITY ANALYSIS

    Sep 1, 2000, 00:00

  • PCV21- VARIATION IN MEDICAL RESOURCE UTILIZATION IN THE MANAGEMENT OF PULMONARY EMBOLISM

    Sep 1, 2000, 00:00

  • PCN9- AN APPROACH TO DESIGNING A MULTINATIONAL MODEL FOR THE CURRENT TREATMENT OF BREAST CANCER

    Sep 1, 2000, 00:00

  • PMH1- THE IMPACT OF DEMENTIA ON THE QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PEOPLE

    Sep 1, 2000, 00:00

  • PGU8- ANALYSIS OF THE DIRECT COST GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHNS DISEASE

    Sep 1, 2000, 00:00

  • PMDQ5- MONETARY VALUE OF QUALITY OF LIFE IMPROVEMENTS

    Sep 1, 2000, 00:00

  • PRS2- COST-EFFECTIVENESS ANALYSIS OF BASIC AND IMMUNOTROPIC THERAPY IN CHILDREN WITH BRONCHIAL ASTHMA

    Sep 1, 2000, 00:00

  • PMH12- DATA TRIANGULATION IN THE ASSESSMENT OF SUBSTANCE ABUSE TREATMENT OUTCOMES IN ADOLESCENT POPULATIONS

    Sep 1, 2000, 00:00

  • PRS1O- AGE AND GENDER DIFFERENCES IN UTILIZATION OF ASTHMA MEDICATION IN CHILDREN AND YOUNG ADULTS IN TAYSIDE, SCOTLAND

    Sep 1, 2000, 00:00

  • PMDH5- TEMPORAL TRENDS AND ETHNIC VARIATIONS IN AMENABLE MORTALITY IN SINGAPORE FROM 1965 TO 1994- THE IMPACT OF HEALTH CARE IN TRANSITION

    Sep 1, 2000, 00:00

  • PMDE5- COST-EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Sep 1, 2000, 00:00

  • PID5- MEDICO-ECONOMIC MODELLING OF INFLUENZA MANAGEMENT IN EUROPE- METHODOLOGY USED IN FRANCE AND GERMANY

    Sep 1, 2000, 00:00

  • PGU4- UTILIZATION AND COSTS OF GASTROINTESTINAL DRUGS IN RELATION TO HELICOBACTER-PYLORI ERADICATION; PHARMACOECONOMIC ANALYSIS FOR THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PNR4- A STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ACUTE TREATMENT STRATEGIES FOR MIGRAINE- THE DISABILITY IN STRATEGIES FOR CARE (DISC) STUDY

    Sep 1, 2000, 00:00

  • RS3- QUALITY OF LIFE OF ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE

    Sep 1, 2000, 00:00

  • PID4- HOSPITAL ANTIBIOTICS UTILIZATION EVALUATION

    Sep 1, 2000, 00:00

  • PAO8- HOSPITAL COSTS, DAYS, AND POST-ACUTE CARE FOR VERTEBRAL FRACTURES IN WOMEN

    Sep 1, 2000, 00:00

  • CV2- EFFECTIVENESS AND COST-EFFECTIVENESS OF EPTIFIBATIDE IN INDIVIDUAL PATIENTS WITH ACUTE CARDIAC ISCHEMIA- THE IMPORTANCE OF RISK STRATIFICATION

    Sep 1, 2000, 00:00

  • Clinical and Economic Outcomes of Coronary Angioplasty Alone or in Combination with Stents in Academic Health Centers- A Retrospective Database Analysis

    Jul 1, 2000, 00:00

  • How Do Italian Pharmacoeconomists Evaluate Indirect Costs?

    Jul 1, 2000, 00:00

  • The Direct Cost of Rheumatoid Arthritis

    Jul 1, 2000, 00:00

  • Data Collection Methods in Prospective Economic Evaluations- How Accurate Are the Results?

    Jul 1, 2000, 00:00

  • The Reliability and Validity of the Impact on Lifestyle Questionnaire in Patients with Acromegaly

    Jul 1, 2000, 00:00

  • Meeting the NICE Requirements- A Markov Model Approach

    Jul 1, 2000, 00:00

  • Modeling the Use of Triple Combination Therapy in Five Countries- Nevirapine, Zidovudine, and Didanosine

    May 1, 2000, 00:00

  • The Use of Conventional Antipsychotic Medications for Patients with Schizophrenia in a Medicaid Population- Therapeutic and Cost Outcomes over 2 Years

    May 1, 2000, 00:00

  • Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data- The Role of Nonrandom Selection and Skewed Data

    May 1, 2000, 00:00

  • Designing Naturalistic Prospective Studies of Economic and Effectiveness Outcomes Associated with Novel Antipsychotic Therapies

    May 1, 2000, 00:00

  • SF-36 as A Predictor of Health States

    May 1, 2000, 00:00

  • Commentary- Pharmacoeconomics and Outcomes Research- Expanding the Healthcare “Outcomes” Market

    May 1, 2000, 00:00

  • PDH19- ANALYSIS OF THE TOTAL COST AND RESOURCES CONSUMED IN CASES OF SINGLE AND CONCURRENT CHRONIC ILLNESS

    Mar 1, 2000, 00:00

  • PCD3- INCIDENCE, UTILIZATION OF HEALTH CARE AND COSTS OF STROKE

    Mar 1, 2000, 00:00

  • PMT37- BENEFITS OF EARLY MODELING IN DRUG DISCOVERY

    Mar 1, 2000, 00:00

  • PMH8- COST-EFFECTIVENESS OF STRATIFIED CARE IN THE MANAGEMENT OF MIGRAINE

    Mar 1, 2000, 00:00

  • PMH28- QUALITY OF LIFE DIFFERENCES BETWEEN PATIENTS WITH EPISODIC AND TRANSFORMED MIGRAINE

    Mar 1, 2000, 00:00

  • Ql- CONSUMER AND STAFF VALIDATION OF A SELF-ADMINISTERED HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR INDIVIDUALS WITH SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PCH7- COST-EFFECTIVENESS OF RITUXIMAB IN RELAPSED, REFRACTORY, LOW-GRADE NON-HODGKINS LYMPHOMA

    Mar 1, 2000, 00:00

  • PMH30- MODELING LENGTH OF PRESCRIPTION THERAPY FOR DEPRESSION PATIENTS

    Mar 1, 2000, 00:00

  • PMT33- LINGUISTIC VALIDATION OF THE VASCULAR QUALITY OF LIFE QUESTIONNAIRE (VASCUQOL) IN 8 LANGUAGES

    Mar 1, 2000, 00:00

  • PCD26- A CLOSER LOOK AT HYPERTENSION PRACTICE PATTERNS AND MEDICATION COMPLIANCE

    Mar 1, 2000, 00:00

  • PHV27- COSTS AND OUTCOMES OF TREATING FEBRILE NEUTROPENIA IN NINE EUROPEAN COUNTRIES

    Mar 1, 2000, 00:00

  • PRN6- DEVELOPING A SPECIFIC HRQL INSTRUMENT FOR OVERACTIVE BLADDER

    Mar 1, 2000, 00:00

  • PMT6- MONITORING THE GATEKEEPER- METHODOLOGIES FOR THE DEVELOPMENT OF PROCESS AND OUTCOME MEASURES FOR THE EVALUATION OF IRBS

    Mar 1, 2000, 00:00

  • PCH14- EFFECTIVENESS OF ERYTHROPOIETIN IN CANCER PATIENTS

    Mar 1, 2000, 00:00

  • PMT36- LINGUISTIC VALIDATION OF THE WORK LIMITATIONS QUESTIONNAIRE (WLQ)

    Mar 1, 2000, 00:00

  • PRS3- TRENDS IN THE USE OF -AGONIST MEDICATIONS IN BRITISH COLUMBIA- AN ANALYSIS OF BC PHARMACARE DATA

    Mar 1, 2000, 00:00

  • DH2- MEDICARES EXTENDED IMMUNOSUPPRESSION COVERAGE IMPROVED MIDDLE-INCOME RENAL GRAFT SURVIVAL

    Mar 1, 2000, 00:00

  • BT3- THE COMPARATIVE ECONOMIC VALUE OF RALTITREXED AND 5-FU PLUS LEUCOVORIN

    Mar 1, 2000, 00:00

  • PMH22- CAN THE BRIEF 'QOLWM' DISCRIMINATE AMONG MIGRAINEURS IN THE COMMUNITY?

    Mar 1, 2000, 00:00

  • PMT5- DEVELOPMENT OF MULTI-LANGUAGE PATIENT OUTCOME ASSESSMENTS

    Mar 1, 2000, 00:00

  • PAR6- QUALITY OF LIFE MEASUREMENTS AS PREDICTORS OF CHANGE IN THERAPY IN PATIENTS WITH MUSCULOSKELETAL DISORDERS

    Mar 1, 2000, 00:00

  • PDH31- HEALTH RELATED QUALITY OF LIFE AND REGULATORY ISSUES- COMPARISON OF US AND EUROPEAN INITIATIVES

    Mar 1, 2000, 00:00

  • PMW3- PRESCRIPTION DRUG USE DURING PREGNANCY- A CLAIMS ANALYSIS

    Mar 1, 2000, 00:00

  • PMH40- ACCESS TO NEW MEDICATIONS TO TREAT SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PCD24- CONJOINT ANALYSIS COMPARING PREFERENCES FOR TREATMENT OUTCOMES IN HEART FAILURE AND HEALTHY PATIENTS- LONGEVITY VERSUS SYMPTOM RELIEF

    Mar 1, 2000, 00:00

  • D2- COST UTILITY OF DOCETAXEL VS VINORELBINE OR PACLITAXEL IN ADVANCED BREAST CANCER

    Mar 1, 2000, 00:00

  • PCD8- A MODEL COMPARING NITROGLYCERIN FORMULATIONS FOR ACUTE ANGINA EPISODES- ASSESSING THE ECONOMIC ISSUES

    Mar 1, 2000, 00:00

  • PSG12- HOSPITAL COST SAVINGS FROM SEVERITY-ADJUSTED LENGTH OF STAY FOLLOWING SURGERY FOR INTRA-ABDOMINAL INFECTION AND TREATMENT WITH PIPERACILLIN/ TAZOBACTAM OR IMIPENEM/CILASTATIN

    Mar 1, 2000, 00:00

  • PMH5- THE EFFECT OF RIVASTIGMINE ON THE DIRECT AND INDIRECT COSTS OF ALZHEIMERS DISEASE

    Mar 1, 2000, 00:00

  • PHV21- PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF PERTUSSIS BOOSTER VACCINATION OF HOSPITAL STAFF

    Mar 1, 2000, 00:00

  • MI1- IDENTIFYING FACTORS ASSOCIATED WITH HIGH AND LOW COST ASTHMATICS- OPPORTUNITIES FOR DISEASE MANAGEMENT USING AUTOMATIC INTERACTION DETECTION

    Mar 1, 2000, 00:00

  • PDH26- A NATIONAL SURVEY OF DECISION-MAKERS IN MANAGED CARE ON THEIR VIEWS AND USE OF PHARMACOECONOMIC INFORMATION

    Mar 1, 2000, 00:00

  • PCH17- CONVENIENCE IS THE MAIN REASON WHY OVARIAN CANCER PATIENTS PREFER ORAL REGIMEN

    Mar 1, 2000, 00:00

  • PCD20- ESTIMATING THE EFFECTS OF POLYPHARMACY ON HOSPITALIZATION IN AN ELDERLY CHF MEDICAID POPULATION

    Mar 1, 2000, 00:00

  • CEB6- THE IMPORTANCE OF COMPARABLE PATIENT POPULATIONS IN COST-EFFECTIVENESS ANALYSES- TOLTERODINE VERSUS OXYBUTININ XL FOR TREATING OVERACTIVE BLADDER

    Mar 1, 2000, 00:00

  • DH4- SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)- IMPACT OF CLINICAL AND FUNCTIONAL STATUS AND TYPE OF MEDICATION TREATMENT ON OUTPATIENT PSYCHIATRIC UTILIZATION

    Mar 1, 2000, 00:00

  • PCH12- RACIAL DIFFERENCES IN THE COST OF TREATING EARLY STAGE PROSTATE CANCER

    Mar 1, 2000, 00:00

  • PCD10- IMPACT OF NEW STATIN DOSES ON MARKET SEGMENTATION

    Mar 1, 2000, 00:00

  • PRS6- CLASSIFYING ASTHMA SEVERITY BASED ON PRESCRIPTION DRUG CLAIMS

    Mar 1, 2000, 00:00

  • PHV16- AN UNUSUAL ECONOMIC EVALUATION OF EFAVIRENZ COMPARED TO INDINAVIR

    Mar 1, 2000, 00:00

  • PHH17- BIPOLAR DISORDER DRUG USE PATTERNS AND COMPLIANCE IN MEDI-CAL POPULATION

    Mar 1, 2000, 00:00

  • PRN3- COST ANALYSIS OF 'OPTIMAL' US DIALYSIS MODALITY UTILIZATION

    Mar 1, 2000, 00:00

  • PRS10- ANNUAL COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PMH38- RESPONSE TO NEFAZODONE, CBASP, AND COMBINED THERAPY- IMPLICATIONS FOR CHRONIC DEPRESSION SEVERITY, FUNCTIONAL STATUS AND ECONOMIC OUTCOMES

    Mar 1, 2000, 00:00

  • PMT2- RELIABILITY OF PRESCRIPTION CLAIMS DATA FOR HEALTH CARE RESEARCH

    Mar 1, 2000, 00:00

  • PMT23- MONTE-CARLO SIMULATION AS AN ALTERNATIVE TECHNIQUE IN ADDRESSING THE UNIT COST VARIABILITY ISSUE

    Mar 1, 2000, 00:00

  • PHT7- THE FRENCH HEALTH UTILITIES INDEX MARK 3

    Mar 1, 2000, 00:00

  • PCD25- SYSTEMATIC REVIEW EVIDENCE ON TREATING HYPERTENSION IN OLDER ADULTS

    Mar 1, 2000, 00:00

  • PMT3- PREDICTING DRUG SPENDING- UPDATE AND EVALUATION OF A REVISED CHRONIC DISEASE SCORE

    Mar 1, 2000, 00:00

  • S2- USE OF ESTROGEN REPLACEMENT THERAPY IN MARYLAND MEDICAID FEMALES

    Mar 1, 2000, 00:00

  • PMT11- METHODOLOGY FOR IDENTIFYING PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES WITHIN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PMH16- USE OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A VETERANS POPULATION

    Mar 1, 2000, 00:00

  • BT1- POSTOPERATIVE PAIN SEVERITY AFTER ABDOMINAL OR ORTHOPEDIC SURGERY- INTERIM RESULTS

    Mar 1, 2000, 00:00

  • PRN2- COST-EFFECTIVENESS OF BASILIXIMAB, DACLIZUMAB, AND OKT3 AS INDUCTION AGENTS IN KIDNEY TRANSPLANTATION

    Mar 1, 2000, 00:00

  • PDH20- CONTENT ANALYSIS OF PHARMACOECONOMIC ADVERTISING IN SPECIALTY AND PRIMARY CARE JOURNALS

    Mar 1, 2000, 00:00

  • PHV7- MANAGING PNEUMOCYSTOSIS- THE COST OF HOSPITALIZATION IN THE US

    Mar 1, 2000, 00:00

  • PHT4- METHODOLOGICAL ISSUES IN ESTIMATING DISEASE PROGRESSION- IS MARKOV MODEL THE BEST METHOD?

    Mar 1, 2000, 00:00

  • PHT14- IMPROVING THE EVIDENCE BASE OF ECONOMIC ANALYSES

    Mar 1, 2000, 00:00

  • PMH15- UTILIZATION OF ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA IN A MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PHV26- EFFECTIVENESS OF ANTIBIOTIC PRESCRIBING AND PATIENT OUTCOMES IN A COMMUNITY SETTING- THE AUSTRALIAN EXPERIENCE

    Mar 1, 2000, 00:00

  • R3- DONEPEZIL USE AND IMPACT ON COST AMONG PATIENTS WITH ALZHEIMERS DISEASE

    Mar 1, 2000, 00:00

  • PCH11- SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY- rhERYTHROPOIETIN (rhEPO) AND QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PMH33- NEUROLEPTIC DRUG EXPOSURE AND TARDIVE DYSKINESIA- A RECORDS-BASED CASE-CONTROL STUDY

    Mar 1, 2000, 00:00

  • PDH27- THE SATISFACTION AND ECONOMIC EVALUATION OF CONVERTING A TRADITIONAL HOSPITAL SYSTEM USING A UNIT DOSE SYSTEM, AT A HOSPITAL IN BARBADOS, WEST INDIES

    Mar 1, 2000, 00:00

  • PSG6- COST-MINIMIZATION ANALYSIS OF EPOETIN ALPHA IN THE COMMUNITY HOSPITAL

    Mar 1, 2000, 00:00

  • PDB2- THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE I DIABETES MELLITUS

    Mar 1, 2000, 00:00

  • PDH3- PHARMACEUTICAL PRICE CONTROLS AND POSITIVE DRUG LIST EFFECTS ON TOTAL AND SOCIAL INSURANCE EXPENDITURES

    Mar 1, 2000, 00:00

  • PCD23- UNADJUSTED INPATIENT COSTS AND MORTALITY FOR FOUR CEREBROVASCULAR EVENTS FOR PATIENTS TREATED AT COMMUNITY TEACHING AND NONTEACHING HOSPITALS

    Mar 1, 2000, 00:00

  • D3- A PHARMACOECONOMIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF TROVAFLOXACIN COMPARED TO CEFTAZIDIME FOR NOSOCOMIAL PNEUMONIA IN A PUBLIC HOSPITAL SETTING IN HONG KONG

    Mar 1, 2000, 00:00

  • PGD4- THE CLINICAL AND ECONOMIC IMPACT OF COMPETING MANAGEMENT STRATEGIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    Mar 1, 2000, 00:00

  • PDB8- HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN TYPE 2 DIABETES

    Mar 1, 2000, 00:00

  • DUC2- INSURANCE CLAIMS COSTS FOR OVERACTIVE BLADDER IN ADULTS

    Mar 1, 2000, 00:00

  • MI4- A FRAMEWORK FOR COST-EFFECTIVENESS ANALYSIS FROM CLINICAL TRIAL DATA

    Mar 1, 2000, 00:00

  • POS4- COST-EFFECTIVENESS OF SCREENING FOR OSTEOPOROSIS IN ELDERLY WOMEN

    Mar 1, 2000, 00:00

  • Q3- HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN AFRICAN AMERICAN MEN WITH PROSTATE CANCER- DATA FROM CaPSURE

    Mar 1, 2000, 00:00

  • R1- QUANTIFYING THE IMPACT OF INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS (STATINS) AND CYTOCHROME P-450 INTERACTING DRUGS ON HEALTHCARE UTILIZATION- A POPULATION-BASED STUDY

    Mar 1, 2000, 00:00

  • PHV12- MANAGEMENT STRATEGIES FOR RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN THE TREATMENT OF HEPATITIS C- CLINICAL AND ECONOMIC IMPLICATIONS

    Mar 1, 2000, 00:00

  • PMT29- THE INFLUENCE OF STATISTICAL ERRORS ON THE COST-EFFECTIVENESS OF TREATMENTS FOLLOWING A PHASE-MI CLINICAL TRIAL

    Mar 1, 2000, 00:00

  • PRN9- THE INFLUENCE OF PHARMACEUTICAL CARE SERVICES ON THE BLOOD PRESSURE OF RENAL TRANSPLANT PATIENTS

    Mar 1, 2000, 00:00

  • CEB1- PHARMACOGENOMICS- EVALUATING THE ECONOMIC IMPACT

    Mar 1, 2000, 00:00

  • PCD22- THE EFFECT OF NATIONALITY ON HEALTH-RELATED QUALITY OF LIFE IN THE GUSTO-I ANGIOGRAPHIC TRIAL

    Mar 1, 2000, 00:00

  • PGD1- OVER-THE-COUNTER NSAID USE AND Gl TOXICITY

    Mar 1, 2000, 00:00

  • PHV11- COST-MINIMIZATION ANALYSIS OF AZITHROMYCIN IV/PO VERSUS CEFUROXIME IV/PO +/- ERYTHROMYCIN IV/PO FOR COMMUNITY-ACQUIRED PNEUMONIA

    Mar 1, 2000, 00:00

  • D4- ECONOMIC ANALYSIS OF WARFARIN IN OUTPATIENTS WITH ATRIAL FIBRILLATION- INNOVATOR VERSUS GENERIC

    Mar 1, 2000, 00:00

  • PHV2- THE BURDEN OF RESPIRATORY SYNCTIAL VIRUS (RSV) HOSPITALIZATIONS IN THE US

    Mar 1, 2000, 00:00

  • PWP1- COMPARATIVE BURDEN OF ILLNESS AT TWO LARGE US COMPANIES

    Mar 1, 2000, 00:00

  • PHT8- DEVELOPMENT OF A NEW SCORING OF THE WOMENS HEALTH QUESTIONNAIRE (WHQ)

    Mar 1, 2000, 00:00

  • PMH4- ANTIPSYCHOTIC MEDICATION TREATMENT PATTERNS AND ASSOCIATED COST OF CARE OF PATIENTS WITH SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PDH21- PRE-POST AND BETWEEN GROUP DIFFERENCES IN PATIENT OUTCOMES IN A PHARMACEUTICAL CARE INTERVENTION PROJECT

    Mar 1, 2000, 00:00

  • PCH9- PATTERNS OF EPOETIN ALPHA UTILIZATION IN ANEMIC CANCER PATIENTS

    Mar 1, 2000, 00:00

  • PCN3- PREDICTORS OF CERVICAL CANCER INPATIENT ADMISSION COSTS BY STAGE

    Mar 1, 2000, 00:00

  • PDB9- COST OF CONCOMITANT ILLNESSES AMONG PATIENTS WITH HYPERTENSION AND DIABETES

    Mar 1, 2000, 00:00

  • PMH1O- A MODEL TO PERFORM ECONOMIC EVALUATIONS OF INTERVENTIONS FOR ACUTE MUSCULAR LOW BACK PAIN

    Mar 1, 2000, 00:00

  • PCD11- THE COST-EFFECTIVENESS ANALYSIS AS A SUBSTANTIATION OF DIAGNOSTIC AND TREATMENT OF EARLY STAGE OF HEART FAILURE

    Mar 1, 2000, 00:00

  • PDB4- COST-EFFECTIVENESS OF DIABETIC FOOT ULCER TREATMENT WITH AUTOLOGOUS PLATELET RELEASATE

    Mar 1, 2000, 00:00

  • PGD2- IMPROVED DRUG COMPLIANCE USING EDUCATION AFFECTS MEDICAL UTILIZATION AND QUALITY OF LIFE FOR PEPTIC ULCER DISEASE PATIENTS

    Mar 1, 2000, 00:00

  • PSG5- THE ECONOMIC IMPACT OF THE USE OF PERFLUORO-N-OCTANE DURING RETINAL DETACHMENT SURGERY

    Mar 1, 2000, 00:00

  • PHH7- COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN CHRONIC SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PMH24- TRANSLATIONS OF THE MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ)- A PSYCHOMETRIC COMPARISON BETWEEN THE ENGLISH, FINNISH, DUTCH, HUNGARIAN, AND SPANISH TRANSLATIONS

    Mar 1, 2000, 00:00

  • CEB2- COST-EFFECTIVENESS OF MENINGOCOCCAL VACCINE IN THE UK

    Mar 1, 2000, 00:00

  • PHW4- MEASUREMENT PROPERTIES OF QUALITY OF LIFE INSTRUMENTS IN ERECTILE DYSFUNCTION (ED)- A REVIEW OF PUBLISHED RESULTS

    Mar 1, 2000, 00:00

  • PAR3- REDUCED UTILIZATION OF ANTIULCERANT DRUGS WITH CELECOXIB- FINDINGS OF THE PAINLESS TRIAL

    Mar 1, 2000, 00:00

  • PHV23- PATIENT ADHERENCE WITH MULTI-DRUG HIV THERAPY- VARIATIONS IN ADHERENCE AND CORRELATION WITH HIV RNA LEVELS

    Mar 1, 2000, 00:00

  • PDH33- EVALUATION AND TREATMENT OF SHORT STATURE- NATIONAL COOPERATIVE GROWTH STUDY (NCGS) EXPERIENCE

    Mar 1, 2000, 00:00

  • PHV5- EFFECTIVENESS AND COSTS OF ANTIBIOTICS IN THE AMBULATORY TREATMENT OF RESPIRATORY TRACT INFECTIONS

    Mar 1, 2000, 00:00

  • PDH32- COST IMPACT OF A PRESCRIPTION BENEFIT CHANGE IN A MEDICARE MANAGED CARE PLAN

    Mar 1, 2000, 00:00

  • PAR7- THE LONGTERM SAFETY AND EFFECTIVENESS OF CYCLOSPORINE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS (RA)

    Mar 1, 2000, 00:00

  • PHV14- A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    Mar 1, 2000, 00:00

  • PSS9- CLINICAL AND ECONOMIC OUTCOMES OF CORONARY ANGIOPLASTY ALONE OR IN COMBINATION WITH STENTS IN ACADEMIC HEALTH CENTERS- A RETROSPECTIVE DATABASE ANALYSIS

    Mar 1, 2000, 00:00

  • PSG1- INPATIENT UTILIZATION OF MEDICAL SERVICES ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE

    Mar 1, 2000, 00:00

  • Q4- MINIMUM MEANINGFUL DIFFERENCE SCORES FOR THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE QUESTIONNAIRE (IBSQOL)

    Mar 1, 2000, 00:00

  • PCN6- COST-EFFECTIVENESS OF GENETIC TESTING IN HEREDITARY NON-POLYPOSIS COLORECTAL CANCER

    Mar 1, 2000, 00:00

  • PCD5- COSTS OF LEFT VENTRICULAR ASSIST DEVICE VERSUS POSITIVE INOTROPIC THERAPY AS A BRIDGE TO HEART TRANSPLANT

    Mar 1, 2000, 00:00

  • PDH9- DRUG AND EXAMINATION IN RELATION TO THE TOTAL THERAPY COSTS-A COST MANAGEMENT DILEMMA?

    Mar 1, 2000, 00:00

  • PMT22- TREATMENT SATISFACTION IN OUTCOMES RESEARCH- AN OVERVIEW OF STUDY MEASURES

    Mar 1, 2000, 00:00

  • PDH2- FACTORS RELATED TO PRESCRIPTION DRUG EXPENDITURE GROWTH- VOLUME VS. PRICE

    Mar 1, 2000, 00:00

  • CAN4- IS PRIOR COMMUNITY ANTIBIOTIC TREATMENT OF PATIENTS HOSPITALISED WITH LOWER RESPIRATORY TRACT INFECTION ASSOCIATED WITH REDUCED IN-HOSPITAL MORTALITY AND LENGTH OF STAY?

    Mar 1, 2000, 00:00

  • PDH23- RELEVANCE OF PHARMACOECONOMICS AND HEALTH OUTCOMES INFORMATION TO HEALTH CARE DECISION-MAKERS IN THE UNITED STATES

    Mar 1, 2000, 00:00

  • PMH29- THE IMPACT OF AN OVER-THE-COUNTER MIGRAINE MEDICATION ON PATIENT QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PMT30- PREFERENCE BASED INDEX FROM THE SF-12

    Mar 1, 2000, 00:00

  • PDH4- TECHNOLOGY ASSESSMENT IN THE US- WHAT DO PAYERS UNDERSTAND AND WHAT INFORMATION DO THEY WANT?

    Mar 1, 2000, 00:00

  • PDB7- TREATMENT COSTS OF TYPE-2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SELECTED CARDIOVASCULAR COMORBIDITIES

    Mar 1, 2000, 00:00

  • PSG8- LONG-TERM OUTCOMES AND RESOURCE USE ASSOCIATED WITH MYOMECTOMY

    Mar 1, 2000, 00:00

  • PMT35- VALUING NON-WORKPLACE PRODUCTIVITY LOST IN MIGRAINEURS- HUMAN CAPITAL APPROACH AND REPLACEMENT COST METHOD

    Mar 1, 2000, 00:00

  • PHV29- VARIABILITY IN THE CRITERIA FOR EARLY SWITCH AND EARLY DISCHARGE IN COMMUNITY-ACQUIRED PNEUMONIA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Mar 1, 2000, 00:00

  • PRS7- DRIVERS OF DIAGNOSIS OF OBSTRUCTIVE LUNG DISEASE, BY STAGE OF SEVERITY

    Mar 1, 2000, 00:00

  • PCN1- OUTCOMES AND COSTS OF ACUTE MYELOID LEUKEMIA OVER ONE YEAR FOLLOWING DIAGNOSIS- AN ANALYSIS OF SEER-MEDICARE DATA

    Mar 1, 2000, 00:00

  • PHV1O- A PRELIMINARY STUDY- THE PHARMACOECONOMIC PROFILE OF ANTIBIOTIC USE IN TURKEY

    Mar 1, 2000, 00:00

  • PCH15- COST-EFFECTIVENESS OF TAMOXIFEN IN BREAST CANCER RISK REDUCTION

    Mar 1, 2000, 00:00

  • PRN1- OVERACTIVE BLADDER COST OF ILLNESS- ANALYSIS OF MEDI-CAL CLAIMS

    Mar 1, 2000, 00:00

  • PAR4- NSAID UTILIZATION AMONG COMMERCIALLY INSURED MEMBERS IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PMH12- THE EFFICIENCY OF DRUG TREATMENT IN FIRST EPISODE SCHIZOPHRENIA- TREATMENT GUIDELINES IN THE UK

    Mar 1, 2000, 00:00

  • PMT25- COMPARATIVE ECONOMETRIC MODELS OF MEDICAL COSTS

    Mar 1, 2000, 00:00

  • PWP3- CONSUMER PREFERENCES FOR DENTAL ANESTHESIA- PUTTING YOUR MONEY WHERE YOUR MOUTH IS

    Mar 1, 2000, 00:00

  • PCD2- ASSESSING THE BURDEN OF ILLNESS IN ELDERLY VERSUS YOUNGER ACUTE CORONARY SYNDROME PATIENTS

    Mar 1, 2000, 00:00

  • PMW5- A PHARMACOECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN THE UNITED KINGDOM AND BELGIUM

    Mar 1, 2000, 00:00

  • PSG4- TRAUMATIC COLON INJURIES- DIFFERENCE IN HOSPITAL COSTS BY TYPE OF SURGICAL REPAIR

    Mar 1, 2000, 00:00

  • PHV30- COSTS AND OUTCOMES OF A RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS PROGRAM IN A MEDICAID MANAGED CARE ORGANIZATION

    Mar 1, 2000, 00:00

  • CAN1- COMPARISON OF COSTS OF ASTHMA TREATMENT BETWEEN PATIENTS TREATED WITH ANTI-INFLAMMATORIES VERSUS BRONCHODILATORS

    Mar 1, 2000, 00:00

  • PDH5- HEALTH CARE EXPENDITURE IN AN HMO BEFORE AND AFTER AN EXCLUSIVE PHARMACY PARTNERSHIP

    Mar 1, 2000, 00:00

  • PRS8- ECONOMIC OUTCOMES OF STEROID INHALER USE PATTERNS IN A MANAGED CARE ORGANIZATION

    Mar 1, 2000, 00:00

  • PMT24- 'CAMOUFLAGED SAMPLING' USING BC MINISTRY OF HEALTH DATA- A METHOD OF RECRUITING SUBJECTS WHILE PRESERVING DATA PRIVACY

    Mar 1, 2000, 00:00

  • PMH19- ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA- DATA FROM THE MEDICAID PROGRAMS OF ALABAMA, GEORGIA, KENTUCKY, AND MICHIGAN

    Mar 1, 2000, 00:00

  • Ml2- THE NUMBER NEEDED TO TREAT APPROACH- EVALUATING THE CLINICAL RELEVANCE OF FEXOFENADINE IN SEASONAL ALLERGIC RHINITIS

    Mar 1, 2000, 00:00

  • POS5- PREVALENCE OF PHARMACOTHERAPY FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • BT4- COST-EFFECTIVENESS OF HIGH VERSUS LOW DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) IN THE TREATMENT OF CHRONIC HEART FAILURE (CHF)- AN ECONOMIC ANALYSIS OF THE US ASSESSMENT OF TREATMENT WITH LISINOPRIL AND SURVIVAL (ATLAS) TR ...

    Mar 1, 2000, 00:00

  • PMH41- PATTERNS OF ANTIDEPRESSANT USE AND CONCOMITANT PSYCHOTHERAPEUTIC AGENTS

    Mar 1, 2000, 00:00

  • POS3- THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) DOES NOT ALLOW IDENTIFICATION OF BELGIAN WOMEN WITH A HIGH RISK OF OSTEOPOROSIS

    Mar 1, 2000, 00:00

  • PDH7- THE IMPACT OF LOCUS OF CONTROL ON COMPLIANCE

    Mar 1, 2000, 00:00

  • PDB6- EVALUATION OF CLINICAL AND DEMOGRAPHIC FACTORS ASSOCIATED WITH DIABETIC FOOT ULCER TREATMENT COSTS

    Mar 1, 2000, 00:00

  • PCN16- VALIDITY OF THE TIME-TRADE OFF TECHNIQUE IN DETERMINING PREFERENCES FOR THE TREATMENT OF PROSTATE CANCER

    Mar 1, 2000, 00:00

  • PMH14- USE OF OLANZAPINE AND RISPERIDONE AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PMH42- THE IMPACT OF ADDING SSRI ANTIDEPRESSANTS TO THE MEDICAID FORMULARY IN CALIFORNIA

    Mar 1, 2000, 00:00

  • PMT1- THE VALUE OF OBSERVATIONAL DATASETS IN THE ECONOMIC EVALUATION OF PHARMACEUTICALS- UK OBSERVATIONS

    Mar 1, 2000, 00:00

  • CAN2- SHORTER HOSPITAL LENGTH OF STAY FOR CORONARY ANGIOPLASTY PATIENTS WHO RECEIVE ABCIXIMAB VERSUS EPTIFIBATIDE ORTIROFIBAN

    Mar 1, 2000, 00:00

  • DUC4- HIGH USERS OF 2-AGONISTS- ARE MEDICAID RECIPIENTS BEING TREATED ACCORDING TO NATIONAL ASTHMA GUIDELINES?

    Mar 1, 2000, 00:00

  • PAR5- COMPARING THE HEALTH RELATED QUALITY OF LIFE OUTCOMES OF TREATMENT FOR EARLY RHEUMATOID ARTHRITIS

    Mar 1, 2000, 00:00

  • PMT15- VALIDATION OF FRAMINGHAM REGRESSION EQUATIONS FOR LOCAL USE

    Mar 1, 2000, 00:00

  • PAR1- THE BURDEN OF EARLY RHEUMATOID ARTHRITIS ON HEALTH RELATED QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PHV6- ECONOMIC EVALUATION OF A SAFETY DEVICE FOR SUBCUTANEOUS INJECTIONS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH)

    Mar 1, 2000, 00:00

  • PMT9- ASSESSING THE COST-EFFECTIVENESS RATIO OF A NEW ANTI-PLATELET AGENT- METHODOLOGIC ISSUES

    Mar 1, 2000, 00:00

  • PMH31- TREATMENT OF CHILDHOOD DEPRESSION IN A MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PWP2- A METHODOLOGY TO MEASURE PRODUCTIVITY OF HEALTH OUTCOMES GROUPS

    Mar 1, 2000, 00:00

  • ICP1- INCORPORATING MEASUREMENT OF INDIRECT COSTS IN THE EVALUATION OF AN ASTHMA HEALTH MANAGEMENT PROGRAM

    Mar 1, 2000, 00:00

  • PDB3- THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE 2 DIABETES MELLITUS

    Mar 1, 2000, 00:00

  • PMH18- USE OF NONBARBITURATE SEDATIVE/ HYPNOTIC AGENTS IN AN AMBULATORY POPULATION

    Mar 1, 2000, 00:00

  • PCH5- COST-EFFECTIVENESS OF EARLY DETECTION AND PREVENTION OF COLORECTAL CANCER BY SCREENING WITH FECAL OCCULT BLOOD TESTS

    Mar 1, 2000, 00:00

  • PCD16- COST-EFFECTIVENESS OF TIROFIBAN PLUS HEPARIN AS COMPARED WITH HEPARIN ONLY IN TREATING UNSTABLE ANGINA

    Mar 1, 2000, 00:00

  • PHV22- UTILIZATION AND COST-EFFECTIVENESS OF ANTIMICROBIALS IN COMMUNITY-ACQUIRED PNEUMONIA

    Mar 1, 2000, 00:00

  • PMH11- TREATMENT GUIDELINES COMPARED TO CLINICAL PRACTICE FOR ACUTE MUSCULAR LOW BACK PAIN

    Mar 1, 2000, 00:00

  • PHV18- SAFETY-NET HOSPITAL PERSPECTIVE- COST-EFFECTIVENESS OF TREATMENT FOR HEPATITIS C

    Mar 1, 2000, 00:00

  • PMH26- CHANGE IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC AGENTS

    Mar 1, 2000, 00:00

  • R4- AVAILABILITY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ASSOCIATED WITH INCREASED SURVIVAL AND LOWER COSTS AT A VA MEDICAL CENTER

    Mar 1, 2000, 00:00

  • PSG3- COSTS INCURRED DURING INPATIENT ADMISSION FOR COMMON SURGERIES- PRELIMINARY RESULTS

    Mar 1, 2000, 00:00

  • PDH1- ECONOMIC IMPLICATIONS FOR SAFETY-NET HOSPITALS- SCREENING FOR HEPATITIS C

    Mar 1, 2000, 00:00

  • PSG2- TEN-YEAR COSTS ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE

    Mar 1, 2000, 00:00

  • PCD4- THE IMPACT OF SECONDARY EVENTS ON THE COST OF ACUTE MYOCARDIAL INFARCTION

    Mar 1, 2000, 00:00

  • CEB5- MEASURING PATIENT PREFERENCES USING CONJOINT ANALYSIS- A NEW APPROACH

    Mar 1, 2000, 00:00

  • PMT20- THE USE OF ECONOMIC ANALYSES IN PRACTICE GUIDELINE DEVELOPMENT

    Mar 1, 2000, 00:00

  • PDB10- ECONOMIC OUTCOMES OF HMG CoA REDUCTASE INHIBITORS IN A HYPERTENSIVE DIABETIC POPULATION IN A MANAGED CARE ORGANIZATION

    Mar 1, 2000, 00:00

  • PDH22- MODELLING THE BENEFITS OF VERTEPORFIN THERAPY IN MACULAR DEGENERATION

    Mar 1, 2000, 00:00

  • ICP2- THE RELATIVE EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN REDUCING WORKER ABSENTEEISM

    Mar 1, 2000, 00:00

  • PMH20- MEDICAL RESOURCES CONSUMPTION BY PATIENTS WITH CHRONIC AND BREAKTHROUGH PAIN

    Mar 1, 2000, 00:00

  • PMT28- HEALTH RELATED QUALITY OF LIFE IN A GENERAL SWEDISH POPULATION WITH A GENDER PERSPECTIVE

    Mar 1, 2000, 00:00

  • PRN8- MEDICAL CARE OF OVERACTIVE BLADDER IN ELDERLY MEDICARE PATIENTS

    Mar 1, 2000, 00:00
  • «
  • 171
  • 172 (current)
  • 173
  • 174
  • 175